The prospective phase I “Flash-Skin I” trial: ultra-high dose rate radiotherapy implementation and quality assurance at a clinical linear accelerator

Riccardo Dal Bello

doi:10.1016/j.radonc.2026.111372

The prospective phase I “Flash-Skin I” trial: ultra-high dose rate radiotherapy implementation and quality assurance at a clinical linear accelerator

2026-01-09

0

PRE

AI

R

Riccardo Dal Bello *

S

S. Psoroulas

D

Dominik Flückiger

J

Jerome Krayenbühl

R

Raphaël Moeckli

C

Claude Bailat

A

Anna Subiel

I

Ileana Silvestre Patallo

J

Jens von der Grün

P

Panagiotis Balermpas

M

Matthias Gückenberger

S

Stephanie Tanadini-Lang

DOI：10.1016/j.radonc.2026.111372

Original

Original request for help

Save

Abstract

En 中文

• The Flash-Skin I (NCT06549439) trial successfully treated 7 patients with 3 × 9 Gy. • A dedicated quality assurance protocol was developed for the eFlash converted linac. • The risk of under-dosage events was minimized with beam tuning. • The total applied dose consistently remained within 5%

The prospective phase I “Flash-Skin I” trial: ultra-high dose rate radiotherapy implementation and quality assurance at a clinical linear accelerator

Abstract

Journal

Organization